DHR Research Update — July 10, 2026
Updated Thesis
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the most recent quarter. Despite this premium, the stock is currently considered cheap relative to its five-year valuation history, with a fair value estimate of $211.54 representing an 8% upside from the current price of $195.98.
The investment grade as of this refresh is B — solid business quality. Good-tier business, cheap-tier valuation
Key Metrics at a Glance
- Revenue growth: +3.7% year over year
- Net margin: 14.9%
- Forward P/E: 37.8x
- Fair value upside: +7.9% to our estimate of $212
Current price: $195.98
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Danaher Corporation remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full DHR research →](/stocks/DHR)